<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The paper is concerned with a study of the effect of metamizil in 45 patients with different forms of vascular <z:hpo ids='HP_0001300'>parkinsonism</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It was established that metamizil exerts a positive effect on the development of neurological symptoms (<z:hpo ids='HP_0002063'>rigidity</z:hpo>, <z:hpo ids='HP_0002067'>bradykinesia</z:hpo>, <z:hpo ids='HP_0001337'>tremor</z:hpo>) in mild and moderately expressed degrees of lesions </plain></SENT>
<SENT sid="2" pm="."><plain>In most of the cases the drugs appeared effective in doses of 0.001 g thrice daily, and in separate cases 0.001 g 6 times daily </plain></SENT>
<SENT sid="3" pm="."><plain>In the majority of patients metazil was tolerated without significant side effects </plain></SENT>
<SENT sid="4" pm="."><plain>In some patients the side effects (<z:hpo ids='HP_0002321'>vertigo</z:hpo>, dryness in the mouth) were slightly expressed </plain></SENT>
<SENT sid="5" pm="."><plain>The effect of treatment was seen after 2 days up to 2 weeks and lasted during the whole course of treatment and sometimes after it </plain></SENT>
<SENT sid="6" pm="."><plain>Metamizil possessing a moderate sedative action, as well as spasmolytical and hypotensive is indicated for patients with vascular <z:hpo ids='HP_0001300'>parkinsonism</z:hpo> </plain></SENT>
</text></document>